Status:
COMPLETED
Bone Mineral Density in Adults With Hyperphenylalaninemia
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborating Sponsors:
BioMarin Pharmaceutical
Conditions:
Phenylketonurias
Eligibility:
All Genders
18+ years
Brief Summary
Hyperphenylalaninemia (HPA) is a rare metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH). Elevated plasma levels of phenylalanine (phe) cause mental retardation, m...
Eligibility Criteria
Inclusion
- Diagnosis of HPA at birth
- Aged 18 or older
Exclusion
- Peri-menopausal women
- Menopausal women
- Patients taking bisphosphonates
- Pregnant women
- Women who have been pregnant within one year of study enrollment
- Women who have breastfed within one year of study enrollment
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT01209819
Start Date
September 1 2010
End Date
October 1 2012
Last Update
June 12 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas Health Science Center at Houston
Houston, Texas, United States, 77030